Academia
Industry executives often lament the fact that clinical trials take a long time to complete and often fail. BioSpace spoke with Tufts’ Ken Getz about possible reasons and solutions.
A new discovery related to the mechanism of the danger signal adenosine triphosphate could influence how immunomodulators, such as vaccines and allergy medications, are formulated.
Dr. Amaka Eneanya told BioSpace that kidney disease, which disproportionately affects people of color, has historically been underrepresented in clinical research compared to other areas of medicine.
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent’s foothold
A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancers that appear to inhibit and promote tumor progression.
Freeline Therapeutics’ hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.
A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.
A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).
In what seems like an unlikely collaboration, Seattle-based Fred Hutchinson Cancer Center (Fred Hutch) is partnering with Amazon to develop cancer vaccines.
Facing the looming threat of AMR, researchers finally have a new clue as to why attempts to develop an effective S. aureus vaccine have failed. BioSpace spoke with the team leaders.
PRESS RELEASES